Isolator Air Handling: Advancements and Considerations for Fill-Finish Processing
In the fill-finish manufacturing of parenteral liquid pharmaceuticals, maintaining product sterility is paramount. The choice of what kind of barrier technology to utilize becomes key,
The Next-Generation Isolator: A User-Friendly Solution for Fill-Finish Professionals
When AST came to the table on the design for our new fill-finish isolator, one of the first areas AST engineers wanted to address
AST Perspectives: Reimagining Fill-Finish Isolator Design
By Steven Ng, CTO & VP of Customer Service This past October, AST announced a groundbreaking collaboration with Germfree on a new fill-finish isolator. This
Toolless Change Parts: A Flexible Solution
Aseptic fill-finish professionals are continually looking to augment their approach to a market that continues to grow and reflect innovations happening around sterile parenteral
AST Perspectives: Looking Towards a Fill-Finish Future Rooted in American Ingenuity
A Word from AST President & CEO Joe Hoff It’s common practice at AST to revisit our Mission Statement as we go about our work
Ready and Sealed: The RTU Advantage for Optimal Vial Sealing
For small-batch, high-value drug products, the aseptic advantages of pre-sterilized ready-to-use vials are clear. To realize the full scope of benefits that RTU vials can
Technology Transfer Strategies: Fill-Finish Automation and Robotics
Throughout the lifecycle of a drug product, many critical target points for optimization make all the difference in the time-to-market equation. A holistic approach to
Preparing for the Small Batch Revolution: Identifying Successful Biopharmaceutical Partnerships
Small-batch manufacturing of liquid pharmaceuticals is slated for exponential growth in the coming years and represents exciting possibilities for the future of medicine and personalized
Fill-Finish for Biosimilars: Ready, Set, Develop!
The last four years have seen remarkable developments in the field of cell and gene therapy. In 2019, the FDA forecasted that the US is likely to add 10-20 cell and gene therapies per year until 2025, and current prognostication has development tracking at that speed.
503 Pharmacies: Integral Partners in the Healthcare Industry
The last four years have seen remarkable developments in the field of cell and gene therapy. In 2019, the FDA forecasted that the US is likely to add 10-20 cell and gene therapies per year until 2025, and current prognostication has development tracking at that speed.